 1. Histological or cytologically-confirmed solid tumor in a patient for whom the study chemotherapy regimen Vincristine plus ifosfamide plus doxorubicin plus etoposide VIDE, Vincristine plus doxorubicin plus cyclophosphamide alternating with ifosfamide plus etoposide VDCIE, Ifosfamide plus vincristine plus actinomycin D IVA or Ifosfamide plus vincristine plus Adriamycin IVAd is considered an appropriate treatment. 